How Deal Making Has Changed Over the Last 12 Months

We're very, very contrarian in how we look at companies. We do AI but we don't do AI for the sake of AI. There aren't many people competing in that space for AI drug discovery companies. Every time we do a deal there's probably one or two other investors looking at that space because everybody's chasing these overhyped AI companies where we don't know which one's the winner.